AR106477A1 - PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDAS - Google Patents
PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDASInfo
- Publication number
- AR106477A1 AR106477A1 ARP160103263A ARP160103263A AR106477A1 AR 106477 A1 AR106477 A1 AR 106477A1 AR P160103263 A ARP160103263 A AR P160103263A AR P160103263 A ARP160103263 A AR P160103263A AR 106477 A1 AR106477 A1 AR 106477A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically effective
- biguanides
- effective salts
- antagonist
- receptor antagonist
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 229940123208 Biguanide Drugs 0.000 abstract 3
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 abstract 3
- 102100029409 Neuromedin-K receptor Human genes 0.000 abstract 3
- 150000004283 biguanides Chemical class 0.000 abstract 3
- 239000002464 receptor antagonist Substances 0.000 abstract 3
- 229940044551 receptor antagonist Drugs 0.000 abstract 3
- 230000002195 synergetic effect Effects 0.000 abstract 3
- QYTBBBAHNIWFOD-NRFANRHFSA-N pavinetant Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(NS(C)(=O)=O)C=1C1=CC=CC=C1 QYTBBBAHNIWFOD-NRFANRHFSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical group N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición sinérgica conformada por antagonista del receptor NK3 o sus sales farmacéuticamente efectivas, y biguanidas o sus sales farmacéuticamente efectivas, para el tratamiento de PCOS y trastornos relacionados. Combinación sinérgica que comprende combinaciones de un antagonista del receptor NK3 o sus sales farmacéuticamente efectivas, y biguanidas o sus sales farmacéuticamente efectivas en una composición farmacéutica en una sola unidad. Métodos para preparar dichas composiciones farmacéuticas por separado en forma de kit que contiene ambos agentes activos, y con métodos para tratar un sujeto con dicha composición. Reivindicación 2: La composición sinérgica de acuerdo con la reivindicación 1, caracterizada porque el antagonista del receptor NK3 se selecciona entre Talnetant (SB223412), AZD-4901 y AZD-2624. Reivindicación 3: La composición sinérgica de acuerdo con la reivindicación 1, caracterizada porque las biguanidas son Metformina.A synergistic composition consisting of NK3 receptor antagonist or its pharmaceutically effective salts, and biguanides or its pharmaceutically effective salts, for the treatment of PCOS and related disorders. Synergistic combination comprising combinations of an NK3 receptor antagonist or its pharmaceutically effective salts, and biguanides or its pharmaceutically effective salts in a pharmaceutical composition in a single unit. Methods for preparing said pharmaceutical compositions separately in kit form containing both active agents, and with methods for treating a subject with said composition. Claim 2: The synergistic composition according to claim 1, characterized in that the NK3 receptor antagonist is selected from Talnetant (SB223412), AZD-4901 and AZD-2624. Claim 3: The synergistic composition according to claim 1, characterized in that the biguanides are Metformin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4102MU2015 | 2015-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106477A1 true AR106477A1 (en) | 2018-01-17 |
Family
ID=57321359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103263A AR106477A1 (en) | 2015-10-29 | 2016-10-26 | PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDAS |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR106477A1 (en) |
| TW (1) | TW201729808A (en) |
| WO (1) | WO2017072629A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110840869A (en) * | 2019-10-15 | 2020-02-28 | 四川大学华西第二医院 | The application of metformin in endometriosis drugs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69531458T2 (en) | 1994-05-27 | 2004-08-05 | Glaxosmithkline S.P.A. | CHINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS |
| EA002124B1 (en) | 1995-11-24 | 2001-12-24 | Смитклайн Бичам С.П.А. | Quinoline derivatives |
| GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| AR004735A1 (en) | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT. |
| GB9524137D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| CO5150149A1 (en) | 1998-11-20 | 2002-04-29 | Smithkline Beecham Spa | PHARMACEUTICAL COMPOSITIONS DERIVED FROM QUINOLINA |
| EP1146873B1 (en) * | 1999-01-25 | 2005-03-16 | Smithkline Beecham Corporation | Anti-androgens and methods for treating disease |
| ATE245156T1 (en) * | 1999-03-11 | 2003-08-15 | Neurogen Corp | ARYL-ANNELLATED DISUBSTITUTED PYRIDINES: NK3 RECEPTOR LIGANDS |
| GB0027701D0 (en) | 2000-11-13 | 2000-12-27 | Smithkline Beecham Spa | Novel compounds |
| US20080194622A1 (en) | 2005-06-23 | 2008-08-14 | Astrazeneca Ab | Quinoline 3-Sulfonate Esters as Nk3 Receptor Modulators |
| MX2010001080A (en) | 2007-08-07 | 2010-03-01 | Hoffmann La Roche | Pyrrolidine aryl-ether as nk3 receptor antagonists. |
| KR101372743B1 (en) | 2009-01-30 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Piperidine derivatives as nk3 receptor antagonists |
| US8318759B2 (en) | 2009-02-18 | 2012-11-27 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives as NK3 receptor antagonists |
| AU2014255512A1 (en) * | 2013-04-19 | 2015-11-12 | Astrazeneca Ab | A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS) |
-
2016
- 2016-10-19 WO PCT/IB2016/056271 patent/WO2017072629A1/en not_active Ceased
- 2016-10-26 AR ARP160103263A patent/AR106477A1/en unknown
- 2016-10-27 TW TW105134672A patent/TW201729808A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201729808A (en) | 2017-09-01 |
| WO2017072629A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017004525A2 (en) | Ror-gamma inhibitory dihydropyrrolopyridines | |
| MX2021009673A (en) | ROR-GAMMA MODULATORS. | |
| SV2017005461A (en) | BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO | |
| CL2018003429A1 (en) | Novel compounds such as autotaxin inhibitors and pharmaceutical compositions that comprise them. | |
| MX381639B (en) | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF DRY EYE DISEASE. | |
| MX2018003388A (en) | Farnesoid x receptor agonists and uses thereof. | |
| MX2016014308A (en) | COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE RECEIVER 7. | |
| UY37098A (en) | ROR-GAMMA MODULATORS | |
| DOP2016000208A (en) | BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS | |
| MX2017002670A (en) | Glycosidase inhibitors. | |
| MX2023001193A (en) | COMPOSITION OF A MASP-2 INHIBITOR ANTIBODY FOR USE IN THE TREATMENT OF A CONDITION ASSOCIATED WITH THE ACTIVATION OF THE MASP-2 DEPENDENT COMPLEMENT. | |
| MX381640B (en) | GIP AGONIST METHODS AND COMPOUNDS. | |
| MX2017015838A (en) | Compositions and methods for treating pterygium. | |
| MX382033B (en) | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA-MEDIATED DISORDERS. | |
| MX2017014375A (en) | Ccr2 modulators. | |
| ZA201906100B (en) | Combination of a ppar agonist with a fxr agonist | |
| CL2017001301A1 (en) | Stabilized ophthalmic compositions of omega 3 | |
| CL2017000845A1 (en) | Lysine Gingipain Inhibitors | |
| MX2018012285A (en) | TREATMENT METHODS FOR COLESTIC AND FIBROTIC DISEASES. | |
| AR110404A1 (en) | METHODS FOR THE TREATMENT OF FIBROTIC DISEASES USING THE INTERFERON-l | |
| CO2017002312A2 (en) | Substituted bicyclic compounds | |
| CR20150653A (en) | NEW COMPOUNDS FOR CANCER TREATMENT | |
| UY36732A (en) | PIRIDIN PIRAZINONAS NOVEDOSAS AS BROMODOMINIUM INHIBITORS OF THE BET FAMILY | |
| AR106477A1 (en) | PHARMACEUTICAL COMBINATION OF ANTAGONIST RECEIVER NK3 AND BIGUANIDAS | |
| MX2021005875A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE, MIODEGENERATIVE AND LYSOSOMIC STORAGE DISORDERS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |